NeuroOne Promotes Emily Johns to Expanded Chief Administrative Officer Role

NeuroOne Medical Technologies Corporation has announced the promotion of Emily Johns to the expanded role of Chief Administrative Officer and General Counsel. The medical technology company, which focuses on improving surgical care options for patients with neurological disorders, made the announcement as part of its ongoing organizational development strategy.

Johns, who joined NeuroOne earlier this year as General Counsel, will continue to lead the company's legal strategy while taking on additional oversight responsibilities. Her expanded role now includes management of all human resources, compliance, security, and risk areas within the organization. This promotion reflects the company's commitment to strengthening its operational infrastructure during a period of planned growth and expansion.

Dave Rosa, President and CEO of NeuroOne, expressed confidence in Johns' capabilities, stating that she has made impactful contributions to the organization and the future growth of the business since joining the company. The leadership team anticipates her continued contributions as NeuroOne scales its operations and expands its market presence in the neurological treatment sector.

Johns brings substantial experience to her expanded role, having most recently served as a partner at Honigman LLP, where she represented numerous companies in the life sciences industry. Her relationship with NeuroOne dates back to 2017, when she began representing the company on all transactional work. Prior to her tenure at Honigman, Johns began her legal career at Sullivan & Cromwell LLP, where she represented public companies in securities offerings and mergers and acquisitions transactions.

In her statement regarding the promotion, Johns expressed honor in stepping into the expanded role and emphasized her commitment to building on the strong foundation established by the NeuroOne team. She highlighted her focus on strengthening operations and infrastructure to help bring the company's life-changing technologies to more patients suffering from neurological conditions.

NeuroOne Medical Technologies Corporation is developing and commercializing minimally invasive and high-definition solutions for EEG recording, stimulation, and ablation for patients suffering from various neurological disorders. The company's technologies target conditions including epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain resulting from failed back surgeries. These innovations aim to improve patient outcomes while reducing procedural costs across the healthcare system.

The company's broader mission extends to potential applications in other medical areas, including depression, mood disorders, pain management, incontinence, high blood pressure, and artificial intelligence integration. This expansion into additional therapeutic areas represents significant growth potential for the company and the broader medical technology sector.

This leadership promotion comes at a critical time for the neurological treatment market, which continues to see increased demand for innovative solutions that can improve patient quality of life while addressing healthcare cost concerns. The consolidation of legal, human resources, compliance, and risk management functions under Johns' leadership suggests a strategic move toward operational efficiency as NeuroOne prepares for potential market expansion and increased commercialization of its technologies.

The implications of this organizational change extend beyond internal operations, potentially influencing investor confidence and market perception of NeuroOne's growth trajectory. For patients suffering from neurological disorders, strengthened corporate leadership could accelerate the availability of new treatment options and improved care methodologies. The medical technology industry more broadly may see this as an indicator of maturation within the neurological device sector, where companies are increasingly focusing on operational excellence alongside technological innovation.

For more information about NeuroOne's technologies and corporate developments, visit https://www.nmtc1.com. Additional details about this announcement can be found at https://www.newmediawire.com.